Harvard School of Public Health refuses tobacco funds
xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">
http://bmj.com/cgi/content/full/324/7335/444/d BMJ 2002;324:444 ( 23 February ) News roundup
Harvard School of Public Health refuses tobacco funds
Fred Charatan Florida Last month, faculty members at the Harvard School of Public Health decided that
it would "not accept any grant or anything else of value from any tobacco
manufacturer, distributor, or other tobacco related company." The vote not to accept research funding from tobacco manufacturers and their
subsidiaries, puts current practice into official policy and is consistent with
Harvard Universitys 13 year old policy of not holding stock in tobacco
companies. "I believe the decision by the faculty represents a powerful statement
from public health professionals that we must all focus on efforts to prevent
the addiction and terrible consequences of tobacco," said Barry Bloom,
dean of the Harvard School. The decision meets general policy that was recently agreed to by the deans
of the 31 member Association of Schools of Public Health so that it could
distribute research funds from the American Legacy Foundation. This public
health foundation was established by the tobacco industrys 1998 settlement of
lawsuits brought by a coalition of attorneys general in 46 states and five US
territories. The Harvard School of Public Health comprises more than 300 faculty members
engaged in teaching and training more than 800 students in a broad spectrum of
disciplines crucial to the health and wellbeing of individuals and populations
around the world. Programmes and projects range from the molecular biology of
AIDS vaccines to the epidemiology of cancer; from risk analysis to violence
prevention; from maternal and child health to quality of care management; and
from healthcare management to international health and human rights.
|